

March 31, 2021

Dear Reviewers,

We appreciate you taking the time to evaluate our manuscript entitled “New insights into renal lipid dysmetabolism in diabetic kidney disease”. We believe that we addressed all concerns raised.

Reviewer 1: Mitrofanova A. et al. provided an interesting review with the focus of renal lipid dysmetabolism in diabetic kidney disease.

1. The abstract should be more clarified with current status, purpose and what are the main advanced knowledge or information;

We thank the reviewer for this comment and we have made changes in the “Abstract” section accordingly (page 1, lines 20-24).

2. The content is substantial, of clear logical tiers and relatively fluently expressed. But, if the author could further rectify the Introduction Part, it would be more attractive.

The “Introduction” section was modified accordingly (page 2, lines 46-53).

3. It is better to add some subtitles.

We have added one more subtitle to the existing ones, which is reflected at the page 5, line 167. We have also modified other subtitles to bold to make it more visible.

4. How about glomerular endothelial cells in the renal lipid dysmetabolism in CKD ? PMID:33409761, PMID:23563804 ;

We thank the reviewer for this important comment and we have included comments on glomerular endothelial cells to the manuscript (page 5, lines 167-168; page 5, lines 173-174).

5. some sentence constructions and small spelling errors need to be modified, such as line 309, S1P recetor ; 6. line 319, In addition 7. line 187, whos derevitation is not entirely clear.

The grammar spelling was revised accordingly.

Reviewer 2: Mitrofanova A et al. summarizes the recent knowledge about the role of lipid metabolism in the development of diabetic kidney disease. Major comments 1) The review consists of 4 sections: cholesterol, triglyceride, lipid droplet and sphingolipids. Is not it better to place the topic of lipid droplet last?

We thank the reviewer for this comment and we have made changes accordingly.

2) The same authors have recently published reviews on the similar topic (Mitrafanova A et al. Curr Opin Pharmacol. 2020; 55:60-72; Ducasa GM et al. Curr Diab Rep. 2019;19(12):144; Mitrafanova A et al. Am J Physiol Renal Physiol. 2019;317(5):F1241-F1252). The authors should explain how the current review is different from them in the introduction.

We thank the reviewer for pointing out to this important concern. Explanations were added to the “Introduction” section (page 2, lines 46-48).

Minor comments: The following typos should be corrected: L35, pdocyte; L124, ezeptimibe; L193, whos etc.

The grammar spelling was revised accordingly.

Sincerely,

A handwritten signature in blue ink, appearing to read 'A. Mitrofanova', with a stylized, cursive script.

Alla Mitrofanova, Ph.D.
Instructor in Research,
Katz Family Division of Nephrology and Hypertension
Department of Surgery
University of Miami Miller School of Medicine
1580 N.W. 10th Avenue, Batchelor Bldg
Miami, FL 33136
Phone 305-243-2577